Pacific Biosciences of California, Inc. (PACB) Posts Q3 EPS Loss of $0.54, Sales Top Expectations

Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q3 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $9.73 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Children's Place (PLCE) Misses Q2 EPS by 20c
• Lennar Corp. (LEN) Misses Q3 EPS by 10c